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Abstract
Background: Hepatitis C Virus (HCV) infection is associated with chronically evolving disease and development of
hepatocellular carcinoma (HCC), albeit the mechanism of HCC induction by HCV is still controversial. The nucleocapsid
(core) protein of HCV has been shown to be directly implicated in cellular transformation and immortalization,
enhancing the effect of oncogenes and decreasing the one of tumor suppressor genes, as RB1 and its protein product
pRB. With the aim of identifying novel molecular mechanisms of hepatocyte transformation by HCV, we examined the
effect of HCV core protein on the expression of the whole Retinoblastoma (RB) family of tumor and growth suppressor
factors, i.e. pRb, p107 and pRb2/p130.
Methods: We used a model system consisting of the HuH-7, HCV-free, human hepatocellular carcinoma cell line and
of the HuH-7-CORE cells derived from the former and constitutively expressing the HCV core protein. We determined
pRb, p107 and pRb2/p130 protein and mRNA amount of the respective genes RB1, RBL1 and RBL2, RBL2 promoter
activity and methylation as well as DNA methyltransferase 1 (DNMT1) and 3b (DNMT3b) expression level. The effect of
pRb2/p130 over-expression on the HCV core-expressing HuH-7-CORE cells was also evaluated.
Results: We found that the HCV core protein expression down-regulated pRb2/p130 protein and mRNA levels
in HuH-7-CORE cells by inducing promoter hyper-methylation with the concomitant up-regulation of DNMT1
and DNMT3b expression. When pRb2/p130 expression was artificially re-established in HuH-7-CORE cells, cell
cycle analysis outlined an accumulation in the G0/G1 phase, as expected.
Conclusions: HCV core appears indeed able to significantly down-regulate the expression and the function of two
out of three RB family tumor and growth suppressor factors, i.e. pRb and pRb2/p130. The functional consequences at
the level of cell cycle regulation, and possibly of more complex cell homeostatic processes, may represent a plausible
molecular mechanism involved in liver transformation by HCV.
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Background
Hepatitis C Virus (HCV), a member of the Flaviviridae
family, has a single-stranded, positive-sense RNA gen-
ome of approximately 9.6 kb in length, which encodes a
large polyprotein precursor of about 3,000 amino acids.
This precursor is subsequently cleaved, by a combination
of host and viral proteases, into at least ten proteins, four
structural proteins [core, envelope 1 (E1), envelope 2 (E2)
and p7] and six non-structural proteins (NS2, NS3, NS4A,
NS4B, NS5A, and NS5B) [1, 2]. Infection by the hepato-
tropic HCV is a leading cause of chronic liver disease,
with more than 170 million chronically infected individ-
uals worldwide [3]. Chronic HCV infection is associated
with the development of chronic hepatitis, fibrosis and
cirrhosis, and is a major risk factor for the development
and progression to hepatocellular carcinoma (HCC) [4].
Despite the successful development of the HCV sub-
genomic replicon and the establishment of the JFH1
infectious virus model, the mechanisms underlying HCV-
mediated tumorigenesis are still not fully understood [5].
It is known that the HCC development associated with
HCV infection is a slow progressing oncogenic process,
probably requiring multiple subsequent steps of genetic
and epigenetic alterations. Indeed, activation of cellular
oncogenes, inactivation of tumor suppressor genes, and
dysregulation of multiple signal transduction pathways
have been reported as possible pro-oncogenic mecha-
nisms of HCV associated tumor [6]. Actually, virus-
encoded factors establish a set of complex interactions
with various cellular proteins and are actively implicated
in several cellular signal transduction pathways that affect
cell survival, proliferation, migration and transformation,
thus contributing to viral persistence and pathogenicity.
[7]. Among the HCV proteins, the 21 kDa core protein
has been shown to modulate cellular genes expression,
being involved in apoptosis, signal transduction, ROS
formation, lipid metabolism, transcriptional activation,
transformation and immune modulation [8–13]. HCV
core binds to host tumor suppressor proteins, such as
p53, p73 and pRb, modulates the expression of the cyclin
dependent inhibitor p21Waf1/Cip1 [14, 15], a major target of
p53, and regulates the activities of cyclin/cyclin-dependent
kinase complexes involved in cell-cycle control and tumor
onset/progression [16]. Furthermore, HCV core protein
may also influence the growth and proliferation of host
cells through activation of signaling pathways such as
Raf/MAPK, Wnt/β-catenin and TGF-β, all known to
be activated in HCC [17]. Lately, several studies have
reported the presence of HCV core mutant proteins in
HCV-infected patients who developed HCC, although
the functional relevance of these mutations on malig-
nant transformation is still not clear [18].
Due to the apparent involvement of the RB1 gene
and its product, pRb, in HCC onset and/or progression
[19, 20], as well as the interplay with HCV infection and
HCV core expression [21, 22], we sought to analyze the
effect of the sole HCV core protein expression on all the
Retinoblastoma (RB) family of tumor and growth suppres-
sor factors, i.e. pRb, p107 and pRb2/p130, the protein
products of the RB1, RBL1 and RBL2 genes, respectively
[23–26]. These proteins are defined “pocket proteins”,
due to the high homology they share at the level of
the so-called pocket region, a domain fundamental for
the accomplishment of their cellular effects [23, 24].
The pocket region is also the preferred target of several
small DNA virus oncoproteins in order to overcome the
growth suppressive properties of these endogenous factors
[27]. The function of all the RB family proteins is post-
translationally regulated by a complex modulation of their
phosphorylation status [28]. They share overlapping func-
tions, but possess also unique traits, often associated with
cell and tissue types [24, 29, 30]. In particular, pRb2/p130
plays an important role in G0 non-proliferating cells,
where it is found in its under-phosphorylated form, the
one able to sequester and block its main E2F partners
(E2F4 and E2F5). When cells re-enter the cell cycle, pRb2/
p130 becomes phosphorylated and the release of the E2F
partners reactivates the transcription of the cell growth-
related genes [31, 32]. pRb2/p130 expression results al-
tered in a number of human cancers, such as lung cancer
[33, 34], endometrial [35], oral squamous cell carcinomas
[36] and leukemias/lymphomas [37]. Available evidences
support that pRb2/p130 may play an essential role in
regulating growth and differentiation also in liver epi-
thelial cells, and its elevated expression in HCCs, a
context in which pRb is frequently down-regulated
[30], has been considered as a possible protective mech-
anism to limit their uncontrolled growth [38]. Consistent
with this, pRb2/p130 over-expression in HepG2 HCC cell
lines results in G0/G1 cell cycle arrest, growth inhibition
in vitro and in vivo, while its down-regulation appears
thus implicated in the progression of the disease [39].
All the above observations prompted us to investigate
on the effects of the HCV core protein on the RB family
genes mRNA and protein expression in human HCC cell
lines, with the aim to estimate the involvement of the
RB family factors in the HCV core protein oncogenic
mechanisms associated with HCV-induced carcinogen-
esis. To this end, we set up a model system composed of
the HuH-7 human hepatocellular carcinoma cell line,
originally established from an HCV-negative liver cancer
patient [40–42], and the HuH-7-CORE cell clones,
obtained from the former and capable to stably express
the HCV core protein. This model appeared suitable for
the investigation of cell cycle-related molecular mecha-
nisms associated with the expression of the HCV core
protein and allowed us to assess the ability of this viral
protein in down-modulating the RB family proteins as
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well as its involvement in some molecular underlying
events.
Methods
Cells transfection and plasmid construction
Human HCC cells HuH-7 were cultured at 37 °C in a
5 % CO2 atmosphere in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % fetal bovine
serum, 100 U/ml penicillin and 100 μg/ml streptomycin
and 1X minimum essential amino acids solution (MEM).
Cell cultures were passed twice a week and culture
medium was changed every other day. Stable cell lines,
expressing the HCV core protein, HuH-7-CORE, were
established by transfection with Lipofectamine 2000 (Invi-
trogen Life Technologies, Carlsbad, CA) of pcCAG39neo
(expressing the core protein) plasmid (constructed by A.
Ruggieri), followed by selection with 400 μg/ml G418
(Geneticin, Gibco Invitrogen). In order to avoid the effect
of G418 selected individual clones, the experiments were
performed with a pool of clones obtained after the selec-
tion in G418 and by trypsinization of multiple clones from
one plate.
pcDNA3Rb2/p130 sense and antisense expression plas-
mids [43] were transfected into HuH-7 and HuH-7-CORE
cell lines with Lipofectamine 2000. Briefly, before transfec-
tion with pcDNA3Rb2 and RBL2 (pRb2/p130) promoter
constructs (see below for plasmid description), HCV
core stable transfectants were cultivated in the absence of
G418 for at least two passages. Cells were plated 24 h
before transfection and grown to 80 % confluence in
serum-free medium; cells were then incubated with
Optimem medium (Invitrogen Life Technologies) under
standard conditions for the first 6 h after transfection;
then the medium was changed to DMEM containing 10 %
fetal calf serum without antibiotics for another 48–72 h,
when they were harvested for cell cycle analysis (Methods
below).
pGL2bRb2P construct containing the full length Rb2/
p130 promoter was obtained from PBS SK vector (kindly
provided by Prof. A. Giordano) by excision, HindIII diges-
tion, of the/HindIII digestion, of the 2,34 k b fragment,
corresponding to the RBL2 promoter region. The excised
fragment was inserted and ligated into the cloning site of
pGL2-Basic vector (Promega, Madison, WI) that was line-
arized by HindIII/SacI digestion before ligation. The
resulting plasmid, pGL2bRb2P, contained the RBL2 pro-
moter region whose functional expression could be evalu-
ated by the induced expression of Firefly Luciferase gene
downstream the cloning site. pGL2bRb2P was trans-
fected into HuH-7 and in HuH-7-CORE cell lines
using Lipofectamine 2000 as above. phRL-TK vector ex-
pressing Renilla Luciferase was co-transfected as an in-
ternal control for normalization of luciferase values.
Western blot analysis
HuH-7 and HuH-7-CORE cells were harvested and dis-
solved in RIPA buffer (Tris-HCl 50 mM, NaCl 150 mM,
1 % sodium desoxycholate, 1 % Triton X-100, 0.1 % SDS,
pH 7.5) or in pRb2/p130 buffer as previously described
[43] supplemented with 1X proteinase inhibitor cocktail
(Sigma Aldrich, Milan, Italy). Cell lysates (25 μg) were
loaded onto a 10 % SDS-PAGE and analyzed under re-
duced conditions. Electrophoretically separated proteins
were transferred on a PVDF membrane and probed
with specific monoclonal antibody for 1.5 h at 37 °C
or overnight at 4 °C. After extensive washing with
TBS-T (Tris-HCl 20 mM, NaCl 137 mM, 0.5 % Tween,
pH 7.6), membranes were incubated with appropriate
HRP-conjugated secondary antibody. Protein bands were
revealed by chemiluminescent substrates (ECL, Amersham
Biosciences, Sweden). Antibodies: anti-HCV core protein
mouse monoclonal antibody (Anogen Yes Biotech Labora-
tories. Ltd, Mississauga, Ontario, Canada) A1/3D1clone;
anti-pRb2/p130 clone (BD Transduction Laboratories,
Franklin Lakes, NJ); anti-pRb H-125 clone (Santa-Cruz Bio-
technology, Santa Cruz, CA)¸ anti-p107 C-18 clone (Santa-
Cruz); secondary antibody anti-mouse-HRP (Amersham
Biosciences, Piscataway, NJ).
Gene expression analysis by qRT-PCR
For the real-time quantitative RT-PCR, total cellular
RNA was extracted from the HuH-7 and HuH-7-CORE
cells using the Epicentre Master Pure RNA Purification
kit according to the manufacturer’s instructions (Epicentre
Biotechnologies, Madison, WI). Total RNA was digested
with DNase I and then subjected to reverse transcription
using high capacity cDNA Reverse Transcription kit (Ap-
plied Biosystems, Branchburg, NJ). Real-time quantitative
PCR was performed using SensiMix SYBR kit (Bioline,
Taunton, MA). The cycling program comprises initial
denaturation at 95 °C for 10 min, 40 cycles of denatur-
ation at 95 °C for 15 sec, annealing at 59 °C for 15 sec,
extension at 72 °C for 15 sec and final extension at 72 °C
for 5 min. DNA amplification was performed using a 7500
Fast Real-time PCR system (Applied Biosystems).
The primer sequences were as follows:
RBL1 (p107) forward: 5’-AAGTGTGAGCCGGTTAC-3’
RBL1 (p107) reverse: 5’-AGGATTACGCACACAAGA-3’
RB1 (pRb) forward: 5’-GAGCTTGGTTAACTTGGG-3’
RB1 (pRb) reverse: 5’-CAGATTCCCCACAGTTCC-3’
RBL2 (pRb2/p130) forward: 5’-GGGTGACTGAAGTT
CGTGCT-3’
RBL2 (pRb2/p130) reverse: 5’-TGTGGTTGGAGATGT
TATGCTC-3’
mRNA levels of all three RB family members were nor-
malized using TATA-box binding protein (TBP). mRNA
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and relative expression profiles were generated using the
comparative Ct method (ΔΔCT) [44, 45].
Luciferase reporter assay
Dual luciferase Reporter Assay System (Promega) kit was
used to measure the reporter luciferase activity induced by
the expression of pRb2/p130 promoter in core expressing
cell lines and in the control HuH-7, according to the
protocol suggested by the manufacturer’s manual. Briefly,
5 × 104 cells/well were plated in a 24-well plate, 24 h be-
fore transfection with 0.6 μg of pGL2bRb2P along with
70 ng/well of Renilla Luciferase expressing plasmid, as
internal control. Forty-eight h after transfection, cells were
lysed directly in wells with 1X PBL buffer and cell lysates
were stored in aliquots at -80 °C or processed immediately
for luciferase assay. For the assay, 20 μg of cell lysate were
mixed with 100 μl of luciferase substrate, and light emis-
sion was measured with the LumiCount Luminometer
(Perkin Elmer, Waltham, MA Life Sciences). The lucifer-
ase activity was normalized to protein concentration,
determined by BCA method (Sigma-Aldrich). The value
obtained was normalized to the Renilla-Luc activity mea-
sured in the corresponding cell extracts. Each experiment
was repeated at least three times prepared in triplicate.
DNA methylation analysis
Bisulfite treatment and recovery of genomic DNA samples
were carried out with the EpiTect Bisulfite kit (Qiagen,
Milan, Italy). Briefly, 2 μg of genomic DNA in 20 μl
volume was used for each reaction and mixed with bisul-
fite mix (85 μl) and DNA protect buffer (35 μl). Bisulfite
conversion was performed on a thermocycler as follows:
95 °C for 5 min, 60 °C for 25 min, 95 °C for 5 min, 60 °C
for 85 min, 95 °C for 5 min, 60 °C for 175 min and 8 °C
indefinitely. The bisulfite-treated DNA was recovered by
EpiTect spin column by following the manufacturer’s
instructions.
PCR, performed using pRb2/p130 primers that distin-
guish methylated (M) from unmethylated (U) sequences,
was carried out in a 50 μl volume containing approxi-
mately 50 ng bisulfite-modified DNA, oligonucleotide
primers (0.3 μM each) and 1x GoTaq Master Mix (Pro-
mega). DNA amplification was carried out with initial
denaturing at 95 °C for 5 min, followed by 40 cycles of
denaturing at 95 °C for 30 sec, annealing for 35 s at
55 °C and extension for 30 s at 72 °C. A final extension
was added for 10 min at 72 °C after the last cycle. DNA
products were electrophoresed on 2 % agarose gels and
visualized by ethidium bromide staining.










The choice of two different experimental systems for
luciferase and Methylation-Specific PCR (MSP) transcrip-
tional assays is due to their specific technical features and
responses.
DNMT1 and DNMT3b mRNA expression analysis
Real-Time quantitative PCR assessment of DNMT1 and
DNMT3b mRNA expression in HuH-7 and HuH-7-
CORE cell lines was performed using the ABI PRISM
7500 Sequence Detection System (Applied Biosystems).
800 ng of total RNA were in vitro reverse-transcribed and
100 ng of cDNA was subjected to Real-Time quantitative
PCR, performed in triplicate using TaqMan chemistry
with primers and probe sets from the Assay-on-Demand
list (Hs00154749_m1 and Hs00171876_m1 - Life Tech-
nologies). 18S RNA co-amplification was used as endogen-
ous control reference.
Cell cycle analysis
Cell cycle progression analysis of HuH-7 and HuH-7-
CORE cell lines transiently expressing pRb2 and their
relative controls was performed by flow cytometry, as
previously described [47]. Cells were fixed and perme-
abilized with ice-cold ethanol for 30 min and then washed
twice in PBS. DNA staining was performed by incubating
cells at 37 °C in PBS containing 40 μg/ml propidium iod-
ide and 0.4 mg/ml DNase-free RNase (type 1-A). Samples
were analyzed by collecting FL2 red fluorescence in a
linear scale at above 620 nm. The percentage of cells in
the different phases of the cell cycle was determined by
ModFIT software analysis. Apoptotic cells and debris were
excluded by these analyses. Each experiment was repeated
three times with duplicate samples.
Statistical analysis
Results are expressed as a mean ± Standard Deviation
(S.D.). Differences between groups were analyzed using
the Student’s two-tailed t test (GraphPad Prism v5).
Difference was considered to be significant if P < 0.05.
Results
HCV core expression and cellular localization in a human
HCC cell line
To investigate the interplay between the HCV core protein
and the cellular factors involved in cell growth and repli-
cation, we engineered the HCV-negative HuH-7 human
HCC cell line in order to constitutively express high levels
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of the HCV core protein from genotype 1b, by transfec-
tion with the plasmid pcCAG39neo (Fig. 1, panel a).
Transfected cell clones stably expressing the HCV core
protein were selected in G418 and named HuH-7-CORE.
The expression of the HCV core protein was assessed by
Western blot (Fig. 1, panel b). HCV core appeared mainly
localized in the cytoplasm, displaying a punctate distribu-
tion in the peri-nuclear area (Fig. 1, panel c).
Modulation of the RB family proteins expression by the
HCV core protein
HCV core protein is known to down-modulate pRb ex-
pression, the product of the RB1 gene, in Rat-1 immor-
talized embryo fibroblasts [21] as well as its activity in
other human liver and non-liver cell systems [22, 48].
In order to examine the effect of the HCV core protein
on the expression of all the RB family proteins, we deter-
mined by Western blot pRb, p107 and pRb2/p130 pro-
tein expression in both HuH-7 (parental) and HuH-7-
CORE (HCV core-expressing) cells (Fig. 2). Cells were
assayed during the logarithmic growth phase and after
that confluence was reached in the culture dish. Consist-
ent with literature data [21], HCV core strongly inhibited
pRb expression in HuH-7-CORE cells (Fig. 2, panel a).
Also pRb2/p130 appeared down-regulated in HCV core-
expressing cells and, interestingly, such effect regarded
essentially the under-phosphorylated, fast-migrating,
form of the protein, the one able to exert growth sup-
pressive properties [24, 49]. In the case of pRb2/p130,
the effect resulted by far more evident when cells
reached the confluence (Fig. 2, panel a). Conversely,
under the same conditions, p107 expression appeared
definitely less affected by the expression of the HCV
core protein (Fig. 2, panel b). α tubulin determination
was employed in both panels a and b as a loading con-
trol. p107 was always detected using a replica gel, due to
its apparent molecular mass, and consequent gel migra-
tion, that partially overlapped with the one of pRb and
pRb2/p130.
We thus determined by quantitative RT-PCR the
mRNA levels related to the three RB family genes, RB1,
RBL1 and RBL2. In HuH-7-CORE cells, when compared
with HuH-7 cells, results showed a significant reduction
in mRNA levels for RB1 and RBL2, while for RBL1 the
reduction appeared less evident (Fig. 2, panel c). Such
mRNA expression results were quite consistent with the
determination of the respective protein levels (Fig. 2,
panels a and b).
HCV core modulates RBL2 promoter activity
In search for the molecular mechanisms underlying
pRb2/p130 down-regulation in HuH-7-CORE cells, we
considered that HCV core is implicated, via promoter
hypermethylation, in the negative modulation of several
cellular genes [50–54]. Therefore, we sought to deter-
mine whether the decreased level of RBL2 mRNA and
protein found in the HuH-7-CORE cells could be related
to a negative modulation of the RBL2 promoter activity.
We transfected the construct pGL2bRb2, containing the
full length RBL2 promoter region [43], linked to a lucif-
erase reporter gene, into both HuH-7 and HuH-7-CORE
cells. Evaluation of the promoter activity indicated that
RBL2 promoter was significantly down-regulated in the
HuH-7-CORE cells when compared with the parental
HuH-7 cells (Fig. 3, panel a), with more than three-fold
decrease of the relative luciferase activity ratio (7.52 ±
1.34 vs. 23.90 ± 2.90, respectively with a statistical signifi-
cance of P < 0.05).
RBL2 epigenetic silencing by CpG methylation
DNA methylation of tumor suppressor genes has been de-
scribed as one of the major epigenetic alterations in HCC
Fig. 1 HCV core protein expression in HuH-7 stable transfectants. a Map of pcCAG39EFneo, the mammalian expression vector for cloning and
expressing HCV core protein fragment (nt 1-191). b Western Blot detection of the HCV core protein constitutively expressed in HuH-7-CORE cell
lysates. β-actin detection in the same blot is shown as loading control. c Immunofluorescence of the HCV core protein expression in HuH-7-CORE
cell lines showing its peri-nuclear localization
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[55] and such epigenetic modulations appear now also
crucial for non-coding RNAs [56]. Considerably high inci-
dence of promoter methylation in genes, like SOCS1 [57],
GSTP1 [58, 59], APC [60], and CDKN2A (p16) [54] has
been observed in HCV-positive HCCs [61, 62]. In
addition, the HCV core protein appears able to up-
regulate the levels of DNMT1 and DNMT3b and to in-
duce promoter hypermethylation of tumor suppressor
genes like E-cadherin and p16, resulting in down-
regulation of their expression [51, 52, 54]. Thus, we
sought to determine whether down-regulation of RBL2
gene transcription in HCV core-expressing human HCC
cell lines could be associated with 5’ CpG islands hyper-
methylation. MSP analysis covering the region abundant
in CpG sequences (Fig. 3, panel b) indicated a significant
RBL2 promoter hypermethylation in HuH-7-CORE cells
when compared with the parental HuH-7 cells, strongly
suggesting the involvement of promoter hypermethylation
as a cause of RBL2 down-regulation in HuH-7-CORE cells.
To further determine the molecular mechanisms through
which HCV core affected RBL2 promoter methylation, we
examined the mRNA expression of DNMT1 and DNMT3b
that have been reported to positively influence HCV repli-
cation in HuH-7 cell line [63, 64]. Consistent with these
previously reported results, we found an up-regulation of
both DNMT1 and DNMT3b mRNA level in HuH-7-
CORE cells, when compared with the parental HuH-7 cells
(Fig. 3, panel c). In spite of an evident increase of transcrip-
tion for both DNMT1 and DNMT3b, statistical significance
was reached for DNMT3b expression only.
Fig. 2 RB family proteins and mRNA modulation in HuH-7 parental and HuH-7-CORE cell lines. a and b Western blot analysis of pRb, pRb2/p130 and
p107 proteins in parental HuH-7 and in core expressing HuH-7-CORE cell lines, showing a marked down-modulation of pRb and the phosphorylated
form of pRb2/p130 in the HuH-7-CORE cell line. c Quantitative PCR determination of mRNA levels relative to the three RB family gene products, as
indicated, in the parental HuH-7 cell line (grey bars, which refer to a 100 % relative amount) and in the HuH-7-CORE cells (black bars) constitutively
expressing HCV core protein. Statistical significance: *P = <0.05; **P = <0.01
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Forced pRb2/p130 expression in HuH-7-CORE cells
The RB pocket proteins are the main controllers of the
G1/S checkpoint in the cell cycle [24]. Consequently,
their down-regulation by HCV core protein facilitates
the transition of the cells toward the S phase. In order
to estimate the specific role of the HCV core protein on
the pRb2/p130 function, we over-expressed pRb2/p130
in the HuH-7-CORE cells through transfection of the
pcDNA3RB2/p130 construct. After cytofluorimetric cell
cycle analysis, we found that pRb2/p130 over-expression
induced a slight, but statistically significant, increase in
the percentage of the cells in G1, when compared with
the mock-transfected HuH-7-CORE cells (Table 1). Con-
comitantly, an average decrease in the percentage of the
S phase cells was detected. Analysis of cell cycle in
HuH-7-CORE cells transfected with the RBL2 antisense
construct was included as a control. The amount of
rescue elicited by pRb2/p130 over-expression in HuH-7-
CORE cells can thus represent the functional role of the
viral protein as a pRb2/p130 antagonist in the G1/S
checkpoint dysregulation.
Discussion
HCC development in patients with chronic HCV infec-
tion is considered a multifactorial process, in which
chronic liver inflammation (cirrhosis) and hepatocellular
injury play an important role. However, HCC can still
Fig. 3 Evaluation of the RBL2 promoter activity, its methylation status
and DNMT1 and DNMT3b mRNA expression in HuH-7 parental and
HuH-7-CORE cell lines. a The pGL2bRb2 construct, containing the
full-length promoter region of RBL2 linked to a luciferase reporter
gene, was constructed and then transfected into HuH-7 and HuH-7-
CORE cell lines. Measure of Luciferase activity (Luc/Renilla ratio)
showed a more than three-fold down-modulation of RBL2 promoter
activity in HuH-7-CORE cells. The values plotted are the mean of three
independent transfections, for each of which two different aliquots
have been analyzed for Luciferase quantitation. Statistical significance:
*P = <0.05. b Methylation-specific PCR (MSP) analysis covering the
region abundant in CpG sequences was carried out on genomic
DNA from HuH-7 and HuH-7-CORE cells. U = Unmethylated; M =
Methylated. c qPCR determination of DNMT1 and DNMT3b mRNA
expression shows its up-regulation in HuH-7-CORE cells with respect
to the parental HuH-7 cell line, whose value has been normalized to 1.
The results shown are the mean of two independent experiments
performed in triplicate. Statistical significance: *P = <0.05
Table 1 HuH-7-CORE cells: cell cycle distribution
Go/G1 (%) S (%) G2/M (%)
HuH-7-CORE (mock) 67 ± 5.8 24.5 ± 5.7 8.7 ± 2.2
HuH-7-CORE (pRb2/p130) 70 ± 7.0 21 ± 6.0 8.7 ± 0.9
HuH-7-CORE (pRb2/p130 as) 66.7 ± 5.6 24.6 ± 4.9 8.67 ± 0.69
Effect of pRb2/p130 over-expression on cell cycle distribution in HuH-7-CORE
cells. HuH-7-CORE cells were transfected with a mock construct or with the
pRb2/p130 construct. pRb2/p130 antisense construct (pRb2/p130 as) was also
included as an additional control
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develop in a small proportion of non-cirrhotic patients
with chronic hepatitis C infection, suggesting a direct
involvement of HCV in hepatocarcinogenesis.
HCV-infected cells are forced by complex viral strat-
egies to increase their survival ability and actively repli-
cate, and HCV proteins are functional effectors evolved
to obtain such goals. The present work enforces the
notion that HCV core protein inhibits the G1/S transi-
tion of the cell cycle, demonstrates that pRb is not the
only viral target to perturb this checkpoint and that a
considerable role is played by targeting the sister protein
pRb2/p130. Here we traced the flow of the events
responsible for pRb2/p130 down-regulation by HCV
core, going up to RBL2 promoter hyper-methylation, a
pretty common mechanism elicited by this viral protein.
Such a loss in cell cycle control at the G1/S boundary
exposes infected hepatocytes to repeated unscheduled
mitoses that, combined with a reduction of the apoptotic
processes, increase exponentially the risk of mitotic
errors, as polyploidy, and ultimately neoplastic trans-
formation [65]. Indeed, HCV is a cancer-associated RNA
virus that functionally retraces some molecular mecha-
nisms usually considered peculiar of the small DNA
viruses [66], i.e. disruption of cell cycle checkpoints,
down-regulation of key oncosuppressor genes, as pRb
and p53, impairment of genomic integrity and mitotic
machinery [67]. All these phenomena obviously concur
in raising and maintaining a transformed cell clone. It is
worth of note, in this context, that HCV core protein is
constantly expressed in hepatocytes during HCV chronic
infection and circulating anti-core antibodies are detect-
able in chronically infected patients.
Conclusions
The observations we describe in the present work
represent another step toward the comprehension of
the molecular mechanisms of HCV-induced liver car-
cinogenesis. The RB family proteins are key regulators
in pivotal cellular processes, e.g. cell cycle, apoptosis,
genomic stability, senescence [23, 68] and the impair-
ment of pRb functions by the HCV core protein has
been widely described. Now we demonstrated that the
pRb cognate protein pRb2/p130, which shares several
functions with pRb, but shows also peculiar features
[24], is likewise down regulated by HCV core and
that this phenomenon is due, at least partially, to an
increase in DNMT1 and DNMT3b activity, with con-
sequent RBL2 promoter hypermethylation and pRb2/
p130 protein down-regulation. Now, another negative
cell cycle regulator appears strongly impaired in its func-
tion, thus strengthening the possibility of a neoplastic
drift.
Being HCV core a key factor in sustaining HCV infec-
tion and subsequent host cell transformation, a better
knowledge at the molecular level of the effects of this
viral protein on the cell machinery can help in combat-
ing HCV infection and HCV-related hepatocarcinoma as
well.
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